Diffuse large B cell lymphoma (DLBCL), the most common non Hodgkin lymphoma (NHL) subtype, is characterized by an aggressive clinical course [1], and standard first line R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemoimmunotherapy results in approximately 60% cure rates [2]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.